Search by Drug Name or NDC

    NDC 00024-5920-02 KEVZARA 150 mg/1.14mL Details

    KEVZARA 150 mg/1.14mL

    KEVZARA is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by sanofi-aventis U.S. LLC. The primary component is SARILUMAB.

    Product Information

    NDC 00024-5920
    Product ID 0024-5920_ca91dfdd-7d4f-4074-bbfd-d8fc21deac46
    Associated GPIs 6650006000D520
    GCN Sequence Number 078046
    GCN Sequence Number Description sarilumab PEN INJCTR 150MG/1.14 SUBCUT
    HIC3 Z2V
    HIC3 Description INTERLEUKIN-6 (IL-6) RECEPTOR INHIBITORS
    GCN 44269
    HICL Sequence Number 044183
    HICL Sequence Number Description SARILUMAB
    Brand/Generic Brand
    Proprietary Name KEVZARA
    Proprietary Name Suffix n/a
    Non-Proprietary Name sarilumab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 150
    Active Ingredient Units mg/1.14mL
    Substance Name SARILUMAB
    Labeler Name sanofi-aventis U.S. LLC
    Pharmaceutical Class Interleukin 6 Receptor Antagonists [MoA], Interleukin-6 Receptor Antagonist [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761037
    Listing Certified Through 2024-12-31

    Package

    NDC 00024-5920-02 (00024592002)

    NDC Package Code 0024-5920-02
    Billing NDC 00024592002
    Package 2 SYRINGE in 1 PACKAGE (0024-5920-02) / 1.14 mL in 1 SYRINGE
    Marketing Start Date 2018-04-13
    NDC Exclude Flag N
    Pricing Information N/A